This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ellaway, C. Articles by Christodoulou, J. Search for Related Content PubMed PubMed Citation Articles by Ellaway, C. Articles by Christodoulou, J. Social Bookmarking                         What's this?

Rett Syndrome: Randomized Controlled Trial of L-Carnitine

Western Sydney Genetics Program, the Royal Alexandra Hospital for Children, Westmead, Australia, Department of Paediatrics and Child Health, University of Sydney, Sydney, Australia

Katrina Williams, FRACP

Department of Paediatrics and Child Health, University of Sydney, Sydney, Australia, Clinical Epidemiology Unit, the Royal Alexandra Hospital for Children, Westmead, Australia

Helen Leonard, MBChB

TVW Telethon Institute for Child Health Research, West Perth, Australia

Gwen Higgins, BPharm, FSHP

Pharmacy Department, the Royal Alexandra Hospital for Children, Westmead, Australia

John Christodoulou, FRACP, PhD

Western Sydney Genetics Program, the Royal Alexandra Hospital for Children, Westmead, Australia, johnch{at}mail.usyd.edu.au, Department of Paediatrics and Child Health, University of Sydney, Sydney, Australia

Rett syndrome is a severe neurodevelopmental disorder of unknown etiology, occurring almost exclusively in female patients. The etiology and functional significance of plasma carnitine deficiency seen in some patients with Rett syndrome is unknown. To investigate whether L-carnitine might be of benefit in Rett syndrome, a randomized, placebo-controlled, double-blind crossover trial of L-carnitine has been completed in 35 subjects. Eight-week treatment phases were completed for both a placebo and L-carnitine. Outcome was measured by parents/caregivers and at medical follow-up using three established tools: the Rett Syndrome Motor Behavioral Assessment, the Hand Apraxia Scale, and the Patient Well-Being Index. Analysis comparing change between baseline and week 8 of treatment for L-carnitine and the placebo showed that both parents/caregivers and medical follow-up detected improvements in the subjects' well-being. In addition, medical review showed an improvement on the Hand Apraxia Scale for a higher proportion of girls on L-carnitine. Identification of predictors of clinical improvement has been limited by the power of the study. These findings suggest that L-carnitine is of benefit in some patients with Rett syndrome. While L-carnitine did not lead to major functional changes in ability, the type of changes reported could still have a substantial impact on the girls and their families. Information is still needed, however, to determine if only subgroups of girls with the disorder are responsive to L-carnitine and the appropriate duration of therapy. ( J Child Neurol 1999;14:162-167).

Journal of Child Neurology, Vol. 14, No. 3, 162-167 (1999)
DOI: 10.1177/088307389901400306


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L S Weaving, C J Ellaway, J Gecz, and J Christodoulou Rett syndrome: clinical review and genetic update J. Med. Genet., January 1, 2005; 42(1): 1 - 7. [Abstract] [Full Text] [PDF]

				J. Christodoulou and L. S. Weaving MECP2 and Beyond: Phenotype--Genotype Correlations in Rett Syndrome J Child Neurol, October 1, 2003; 18(10): 669 - 674. [Abstract] [PDF]

				L Colvin, S Fyfe, S Leonard, T Schiavello, C Ellaway, N de Klerk, J Christodoulou, M Msall, and H Leonard Describing the phenotype in Rett syndrome using a population database Arch. Dis. Child., January 1, 2003; 88(1): 38 - 43. [Abstract] [Full Text] [PDF]